Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Caitlin Roberts
CG
Caitlin Roberts
Canaccord Genuity
Wall Street Analyst
★★★☆☆
#1073
on 13Foresight · ranked by our own returns
50%
Success Rate
+0.4%
Average Return
8 of 16 calls profitable · -2.4% vs benchmark
📈 Across the calls we could measure, roughly 50% of Caitlin Roberts's ratings turned a profit when each position was held for 1 year — averaging +0.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

83 Buy 22 Hold 0 Sell
Caitlin's Stock Coverage 16 ratings · 2026-06-21
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
BVS
Bioventus
 Jun 15, 2026 BUY Strong Buy
+41.0% avg upside
8 analysts
$15.00
72.17% Upside
 +0.4%
SNN
Smith & Nephew Snats
 Jun 10, 2026 HOLD Buy
+11.8% avg upside
14 analysts
$30.00
0.23% Downside
 ·
KIDS
OrthoPediatrics
 Jun 02, 2026 BUY Strong Buy
+59.0% avg upside
10 analysts
$25.00
32.44% Upside
 ·
OFIX
Orthofix Medical
 May 22, 2026 BUY Strong Buy
+207.1% avg upside
15 analysts
$18.00
90.51% Upside
 ·
INMD
InMode
 May 21, 2026 HOLD Buy
+41.7% avg upside
9 analysts
$15.00
11.93% Upside
 -3.4%
ESTA
Establishment Labs Holdings
 May 18, 2026 BUY Strong Buy
-1.6% avg upside
12 analysts
$90.00
6.08% Upside
 +29.2%
TELA
TELA Bio
 May 12, 2026 BUY Strong Buy
+1023.6% avg upside
8 analysts
$2.00
149.77% Upside
 -2.9%
SIBN
SI-Bone
 May 11, 2026 BUY Strong Buy
+60.4% avg upside
18 analysts
$27.00
70.54% Upside
 +22.0%
ENOV
Enovis
 May 11, 2026 BUY Strong Buy
+216.5% avg upside
37 analysts
$50.00
127.63% Upside
 +0.4%
VCEL
Vericel
 May 07, 2026 BUY Strong Buy
+13.9% avg upside
16 analysts
$58.00
44.60% Upside
 -6.1%
KRMD
REPRO-MED Systems
 May 06, 2026 BUY Strong Buy
+65.0% avg upside
9 analysts
$6.00
53.78% Upside
 +3.2%
AXGN
AxoGen
 May 04, 2026 BUY Strong Buy
-25.7% avg upside
21 analysts
$50.00
11.45% Upside
 +4.5%
ZBH
Zimmer Biomet Holdings
 Apr 29, 2026 HOLD Buy
+27.6% avg upside
37 analysts
$83.00
5.60% Downside
 +10.8%
SYK
Stryker
 Apr 24, 2026 BUY Strong Buy
+24.0% avg upside
36 analysts
$435.00
41.32% Upside
 -8.1%
ATEC
Alphatec Holdings
 Apr 24, 2026 BUY Strong Buy
+112.9% avg upside
22 analysts
$25.00
183.75% Upside
 -25.8%
GMED
Globus Medical
 Feb 25, 2026 BUY Strong Buy
+21.0% avg upside
24 analysts
$115.00
45.20% Upside
 -16.4%
🔒 11 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Caitlin Roberts — Frequently Asked Questions
How accurate are Caitlin Roberts's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Caitlin's ratings were profitable over a one-year hold, with an average return of +0.4% per rating, or -2.4% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Caitlin ranked on 13Foresight?
Caitlin Roberts is currently ranked #1073 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Caitlin cover?
Caitlin most recently has ratings on BVS, SNN, KIDS, OFIX, INMD, ESTA, TELA, SIBN, ENOV, VCEL, KRMD, AXGN and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.